
    
      The investigators will assess the 18-month safety and potential efficacy of autologous MSCs
      as therapy for ADPKD. A total of 6 patients with ADPKD IV injection of high doses 2Ã—106 of
      autologous mesenchymal stem cells / kg their weight, which will be derived from biopsies of
      their bone marrow. Assessments will be made at 1, 3, 6, 12 and 18 months after cell
      injection. Changes in GFR rate were evaluated by scan isotope.
    
  